Related references
Note: Only part of the references are listed.Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma
Keith T. Flaherty et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
Kevin B. Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Differential inhibitory effects of two Raf-targeting drugs, sorafenib and PLX4720, on the growth of multidrug-resistant cells
Ki-Hwan Eum et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2013)
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2013)
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Meghna Das Thakur et al.
NATURE (2013)
Therapy for metastatic melanoma: the past, present, and future
Laura Finn et al.
BMC MEDICINE (2012)
Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438)
Kim A. Margolin et al.
CLINICAL CANCER RESEARCH (2012)
RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors
Yingjun Su et al.
CLINICAL CANCER RESEARCH (2012)
Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma
Sapna P. Patel et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Melanoma: from mutations to medicine
Hensin Tsao et al.
GENES & DEVELOPMENT (2012)
A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy
Gyoergy Bodoky et al.
INVESTIGATIONAL NEW DRUGS (2012)
Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)
Thomas F. Gajewski et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
CEP-32496: A Novel Orally Active BRAFV600E Inhibitor with Selective Cellular and In Vivo Antitumor Activity
Joyce James et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
Gerald S. Falchook et al.
LANCET (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
Gerald S. Falchook et al.
LANCET ONCOLOGY (2012)
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
Jeffrey R. Infante et al.
LANCET ONCOLOGY (2012)
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
Georgina V. Long et al.
LANCET ONCOLOGY (2012)
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma
Sergey I. Nikolaev et al.
NATURE GENETICS (2012)
Vemurafenib: the first drug approved for BRAF-mutant cancer
Gideon Bollag et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition
W. Deng et al.
PIGMENT CELL & MELANOMA RESEARCH (2012)
Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis
J. -H. Lee et al.
BRITISH JOURNAL OF DERMATOLOGY (2011)
Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer
Peter D. Boasberg et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
Kim H. T. Paraiso et al.
CANCER RESEARCH (2011)
GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
Aidan G. Gilmartin et al.
CLINICAL CANCER RESEARCH (2011)
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
Nikhil Wagle et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The Farnesyl Transferase Inhibitor Lonafarnib Inhibits mTOR Signaling and Enforces Sorafenib-Induced Apoptosis in Melanoma Cells
Heike Niessner et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2011)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikos I. Poulikakos et al.
NATURE (2011)
BRAF targeted therapy changes the treatment paradigm in melanoma
Antoni Ribas et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma
Bianca Devitt et al.
PIGMENT CELL & MELANOMA RESEARCH (2011)
Use of DNA Microarray and Small Animal Positron Emission Tomography in Preclinical Drug Evaluation of RAF265, a Novel B-Raf/VEGFR-2 lInhibitor
Jeffrey R. Tseng et al.
NEOPLASIA (2011)
Targeting the MAPK pathway in melanoma: Why some approaches succeed and other fail
Gajanan S. Inamdar et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
Jessie Villanueva et al.
CANCER CELL (2010)
Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells
Hang Zheng et al.
CANCER LETTERS (2010)
RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models
Hong Yang et al.
CANCER RESEARCH (2010)
An Oncogenic Role for ETV1 in Melanoma
Judit Jane-Valbuena et al.
CANCER RESEARCH (2010)
Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in Braf-Mutant Human Cutaneous Melanoma Cells
Y. N. Vashisht Gopal et al.
CANCER RESEARCH (2010)
Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
Andrea Boni et al.
CANCER RESEARCH (2010)
The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer
Udai Banerji et al.
CLINICAL CANCER RESEARCH (2010)
Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib
Pearlie K. Epling-Burnette et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
BRAF Inhibitors: Research Accelerates in Wake of Positive Findings
Vicki Brower
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Gideon Bollag et al.
NATURE (2010)
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Cory M. Johannessen et al.
NATURE (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells
Ruth Halaban et al.
PIGMENT CELL & MELANOMA RESEARCH (2010)
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
Eric W. Joseph et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Oncogenic Braf Induces Melanocyte Senescence and Melanoma in Mice
Nathalie Dhomen et al.
CANCER CELL (2009)
Targeting the RAF-MEK-ERK pathway in cancer therapy
Clara Montagut et al.
CANCER LETTERS (2009)
Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression
Klaus P. Hoeflich et al.
CANCER RESEARCH (2009)
Rnd3 Regulation of the Actin Cytoskeleton Promotes Melanoma Migration and Invasive Outgrowth in Three Dimensions
R. Matthew Klein et al.
CANCER RESEARCH (2009)
Melanoma and Immunotherapy
Alexander M. M. Eggermont et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2009)
BRAF Signaling and Targeted Therapies in Melanoma
Nathalie Dhomen et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2009)
Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
Axel Hauschild et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A dimerization-dependent mechanism drives RAF catalytic activation
Thanashan Rajakulendran et al.
NATURE (2009)
BrafV600E cooperates with Pten loss to induce metastatic melanoma
David Dankort et al.
NATURE GENETICS (2009)
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma
Clara Montagut et al.
CANCER RESEARCH (2008)
The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel
Nikolas K. Haass et al.
CLINICAL CANCER RESEARCH (2008)
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: A report from the 11715 study group
David F. McDermott et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers
Alex A. Adjei et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
B-RAF regulation of Rnd3 participates in actin cytoskeletal and focal adhesion organization
R. Matthew Klein et al.
MOLECULAR BIOLOGY OF THE CELL (2008)
Farnesyl transferase inhibitors induce extended remissions in transgenic mice with mature B cell lymphomas
Kenneth A. Field et al.
MOLECULAR CANCER (2008)
Understanding signaling cascades in melanoma
Pablo Lopez-Bergami et al.
PHOTOCHEMISTRY AND PHOTOBIOLOGY (2008)
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
James Tsai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
BRAFE600 in benign and malignant human tumours
C. Michaloglou et al.
ONCOGENE (2008)
Treatments for metastatic melanoma: Synthesis of evidence from randomized trials
Philip Lui et al.
CANCER TREATMENT REVIEWS (2007)
Ras oncogenes and their downstream targets
Krishnaraj Rajalingam et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2007)
Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice
Seungwon Kim et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor
Tammie C. Yeh et al.
CLINICAL CANCER RESEARCH (2007)
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
Li Liu et al.
CANCER RESEARCH (2006)
Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885
Alastair J. King et al.
CANCER RESEARCH (2006)
NRAS and BRAF mutations in melanoma turnours in re ation to clinical characteristics:: a study based on mutation screening by pyrosequencing
Esther Edlundh-Rose et al.
MELANOMA RESEARCH (2006)
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The oblimersen melanoma study group
Agop Y. Bedikian et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Scott Wilhelm et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
T. Eisen et al.
BRITISH JOURNAL OF CANCER (2006)
Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases
Arati Sharma et al.
CANCER RESEARCH (2006)
Role of Raf kinase in cancer: Therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway
Jared A. Gollob et al.
SEMINARS IN ONCOLOGY (2006)
The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells
Hidetoshi Sumimoto et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Mechanisms of disease - Melanoma
Arlo J. Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression
ZJ Liu et al.
CANCER RESEARCH (2006)
Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma
DJ Panka et al.
CLINICAL CANCER RESEARCH (2006)
Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome
P Rodriguez-Viciana et al.
SCIENCE (2006)
Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome
T Niihori et al.
NATURE GENETICS (2006)
Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway
CA Granville et al.
CLINICAL CANCER RESEARCH (2006)
BRAF mutation predicts sensitivity to MEK inhibition
DB Solit et al.
NATURE (2006)
Oncogenic BRAF is required for tumor growth and maintenance in melanoma models
MP Hoeflich et al.
CANCER RESEARCH (2006)
Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma
Vikas K. Goel et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling - Role in FTI enhancement of taxane and tamoxifen anti-tumor activity
AD Basso et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies
PM LoRusso et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
LA Garraway et al.
NATURE (2005)
Use of human tissue to assess the oncogenic activity of melanoma-associated mutations
Y Chudnovsky et al.
NATURE GENETICS (2005)
Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells
M Eskandarpour et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background
J Ackermann et al.
CANCER RESEARCH (2005)
Mutant V599EB-RAF regulates growth and vascular development of malignant melanoma tumors
A Sharma et al.
CANCER RESEARCH (2005)
The Ras superfamily at a glance
K Wennerberg et al.
JOURNAL OF CELL SCIENCE (2005)
BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma
EE Patton et al.
CURRENT BIOLOGY (2005)
Development of farnesyl transferase inhibitors: A review
NMGM Appels et al.
ONCOLOGIST (2005)
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma:: A phase III study
MF Avril et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma
H Tsao et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2004)
B-RAF is a therapeutic target in melanoma
M Karasarides et al.
ONCOGENE (2004)
MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol
AM Domina et al.
ONCOGENE (2004)
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer
J Rinehart et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
The RAF proteins take centre stage
C Wellbrock et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity
H Harada et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Deregulated Akt3 activity promotes development of malignant melanoma
JM Stahl et al.
CANCER RESEARCH (2004)
Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways
WT Jia et al.
BLOOD (2003)
Metastasis suppressor pathways - an evolving paradigm
LA Shevde et al.
CANCER LETTERS (2003)
Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells
KSM Smalley et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
PTEN signaling pathways in melanoma
H Wu et al.
ONCOGENE (2003)
A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?
KSM Smalley
INTERNATIONAL JOURNAL OF CANCER (2003)
Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling
B Govindarajan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
High frequency of BRAF mutations in nevi
PM Pollock et al.
NATURE GENETICS (2003)
Mutations of the BRAF gene in benign and malignant melanocytic lesions
AS Yazdi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2003)
Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases
GL Johnson et al.
SCIENCE (2002)
PKB binding proteins: Getting in on the akt
DP Brazil et al.
CELL (2002)
Transient and sustained ERK phosphorylation and nuclear translocation in growth control
T Adachi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2002)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer
M Crul et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
U0126, a mitogen-activated protein kinase kinase inhibitor, inhibits the invasion of human A375 melanoma cells
XK Ge et al.
CANCER LETTERS (2002)
Farnesyl thiosalicylic acid inhibits the growth of melanoma cells through a combination of cytostatic and pro-apoptotic effects
KSM Smalley et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Medium-dose UVA1 phototherapy in localized scleroderma and its effect in CD34-positive dendritic cells
NR Camacho et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2001)
Integrin-mediated adhesion regulates ERK nuclear translocation and phosphorylation of Elk-1
AE Aplin et al.
JOURNAL OF CELL BIOLOGY (2001)
Conformational restriction of flexible ligands guided by the transferred NOE experiment: Potent macrocyclic inhibitors of farnesyltransferase
CJ Dinsmore et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2001)
Phase I and pharmacokinetic study of the ovally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors
CJA Punt et al.
ANTI-CANCER DRUGS (2001)
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
MR Middleton et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
